Literature DB >> 17554702

Association of the outcome of renal transplantation with antibody response to cytomegalovirus strain-specific glycoprotein H epitopes.

Kei Ishibashi1, Tadahiko Tokumoto, Kazunari Tanabe, Hiroki Shirakawa, Koichi Hashimoto, Nobuhiro Kushida, Tomohiko Yanagida, Naoki Inoue, Osamu Yamaguchi, Hiroshi Toma, Tatsuo Suzutani.   

Abstract

BACKGROUND: Cytomegalovirus (CMV) is the most important pathogen affecting the outcome of renal transplantation. The combination of CMV-seronegative transplant recipients with CMV-seropositive transplant donors places recipients at the highest risk of CMV disease. In cases of congenital CMV infection, existing immunity only partially protected mothers from reinfection with a different genotypic strain. The effect of differences in infected CMV strains between CMV-seropositive transplant donors and CMV seropositive transplant recipients on the outcome of transplantation remains unclear.
METHODS: In this prospective multicenter study, the presence of antibodies against strain-specific glycoprotein H epitopes in 84 CMV-seropositive transplant donor/CMV-seropositive transplant recipient renal transplantation cases were determined, and their relationships to acute transplant rejection, CMV infection, degree of antigenemia, and CMV disease were evaluated.
RESULTS: Among the 84 donor/recipient pairs, 45 and 32 had matched and mismatched strain-specific glycoprotein H antibodies, respectively. Acute transplant rejection in the mismatched group was more frequent than it was in the matched group (63% vs. 22%; P=.005). CMV disease was also more frequently observed in the mismatched group (28% vs. 9%; P=.026). The mismatched group had a higher level of antigenemia (P=.019).
CONCLUSIONS: Our results illustrate more adverse events in the cases with a CMV-seropositive transplant donor and a CMV-seropositive transplant recipient in which the glycoprotein H antibodies are mismatched, suggesting that reinfection with a different CMV strain results in more complications.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17554702     DOI: 10.1086/518571

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  15 in total

1.  A novel real-time PCR method for determination and quantification of each cytomegalovirus glycoprotein H subtype in clinical samples.

Authors:  Kazufumi Ikuta; Ken Ishioka; Yuka Sato; Takashi Imamura; Kimisato Asano; Shin Koyano; Naoki Inoue; Tatsuo Suzutani
Journal:  J Clin Microbiol       Date:  2011-11-23       Impact factor: 5.948

2.  Enzyme-linked immunosorbent assay method for detection of cytomegalovirus strain-specific antibody responses.

Authors:  Zdenek Novak; Shannon A Ross; Raj Kumar Patro; Sunil Kumar Pati; Meera K Reddy; Misty Purser; William J Britt; Suresh B Boppana
Journal:  Clin Vaccine Immunol       Date:  2008-11-26

Review 3.  Virion Glycoprotein-Mediated Immune Evasion by Human Cytomegalovirus: a Sticky Virus Makes a Slick Getaway.

Authors:  Thomas J Gardner; Domenico Tortorella
Journal:  Microbiol Mol Biol Rev       Date:  2016-06-15       Impact factor: 11.056

Review 4.  The immunological underpinnings of vaccinations to prevent cytomegalovirus disease.

Authors:  A Louise McCormick; Edward S Mocarski
Journal:  Cell Mol Immunol       Date:  2014-12-29       Impact factor: 11.530

5.  Strain-specific neutralizing antibody responses against human cytomegalovirus envelope glycoprotein N.

Authors:  Sunil K Pati; Zdenek Novak; Misty Purser; Nitin Arora; Michael Mach; William J Britt; Suresh B Boppana
Journal:  Clin Vaccine Immunol       Date:  2012-04-04

6.  Cytomegalovirus vaccine strain towne-derived dense bodies induce broad cellular immune responses and neutralizing antibodies that prevent infection of fibroblasts and epithelial cells.

Authors:  Corinne Cayatte; Kirsten Schneider-Ohrum; Zhaoti Wang; Alivelu Irrinki; Nga Nguyen; Janine Lu; Christine Nelson; Esteban Servat; Lorraine Gemmell; Andrzej Citkowicz; Yi Liu; Gregory Hayes; Jennifer Woo; Gary Van Nest; Hong Jin; Gregory Duke; A Louise McCormick
Journal:  J Virol       Date:  2013-08-07       Impact factor: 5.103

Review 7.  Cytomegalovirus vaccine development.

Authors:  M R Schleiss
Journal:  Curr Top Microbiol Immunol       Date:  2008       Impact factor: 4.291

8.  Impaired direct priming of CD8 T cells by donor-derived cytomegalovirus following kidney transplantation.

Authors:  Shazia Shabir; Baksho Kaul; Annette Pachnio; Gemma D Banham; Helen Smith; Sourabh Chand; Seema Jham; Lorraine Harper; Simon Ball; Afsar Rahbar; Cecilia Söderberg-Nauclér; Paul Moss; Richard Borrows
Journal:  J Am Soc Nephrol       Date:  2013-07-11       Impact factor: 10.121

9.  Cytomegalovirus reinfections in healthy seroimmune women.

Authors:  Shannon A Ross; Nitin Arora; Zdenek Novak; Karen B Fowler; William J Britt; Suresh B Boppana
Journal:  J Infect Dis       Date:  2010-02-01       Impact factor: 5.226

Review 10.  Common Polymorphisms in the Glycoproteins of Human Cytomegalovirus and Associated Strain-Specific Immunity.

Authors:  Hsuan-Yuan Wang; Sarah M Valencia; Susanne P Pfeifer; Jeffrey D Jensen; Timothy F Kowalik; Sallie R Permar
Journal:  Viruses       Date:  2021-06-09       Impact factor: 5.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.